Benlysta's SRI Endpoint Creating Lupus Pathway
By Trista Morrison
Monday, November 22, 2010
After half a century with no new drug approvals and no clear regulatory pathway, the lupus field is finally seeing some progress. And the trial design that helped Human Genome Sciences Inc.'s lupus drug Benlysta (belimumab) achieve Phase III success and win an FDA advisory committee's support last week is already being emulated by up-and-comers in the field, some of which are applying their own spin.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.